The maker of baby shampoo, contraceptives and biologic products on last described a 2 percent increase in earnings for the quarter that completed Sept. 30, but that was due to a $196 million leap in other earnings from divestitures and a smaller tax bill. Third-quarter snare earnings bordered up to $3.42 billion, or $1.23 per share, beating analysts' expectations of $1.15 per share. A year earlier, snare earnings were $3.35 billion, or $1.20 per share.
What are the effects?
Baby shampoos, lotions and powders may expose infants to chemicals ...